These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8465432)

  • 1. OKT3 antibody response study: comparative testing of human antimouse antibody.
    Kimball JA; Norman DJ; Shield CF; Schroeder TJ; Lisi P; Garovoy M; O'Connell JB; Stuart F; McDiarmid SV; Wall W
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):74-6. PubMed ID: 8465432
    [No Abstract]   [Full Text] [Related]  

  • 2. OKT3 antibody response study (OARS): a multicenter comparative study.
    Kimball JA; Norman DJ; Shield CF; Schroeder TJ; Lisi P; Garovoy M; O'Connell JB; Stuart F; McDiarmid SV; Wall W
    Transplant Proc; 1993 Feb; 25(1 Pt 1):558-60. PubMed ID: 8438413
    [No Abstract]   [Full Text] [Related]  

  • 3. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
    Shield CF
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibody response to OKT3 and methods for monitoring.
    Schroeder TJ; Hariharan S; First MR
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):77-80. PubMed ID: 8465433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of inhibitory anti-OKT3 antibodies in renal transplant patients.
    Lamm LU; Mathiasen D; Povlsen JV; Pedersen EB; Birkeland SA; Jørgensen KA
    Transplant Proc; 1994 Jun; 26(3):1730. PubMed ID: 8030107
    [No Abstract]   [Full Text] [Related]  

  • 6. Value of monoclonal antibody OKT3 in solid organ transplantation: a meta-analysis.
    Carrier M; Jenicek M; Pelletier LC
    Transplant Proc; 1992 Dec; 24(6):2586-91. PubMed ID: 1465874
    [No Abstract]   [Full Text] [Related]  

  • 7. The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation.
    Kimball JA; Norman DJ; Shield CF; Schroeder TJ; Lisi P; Garovoy M; O'Connell JB; Stuart F; McDiarmid SV; Wall W
    Transpl Immunol; 1995 Sep; 3(3):212-21. PubMed ID: 8581409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimouse antibody response after OKT3 administration for steroid resistant rejection.
    Kaiser BA; Palmer JA; Dunn SP; Mochon MA; Bartosh SM; Schulman SL; Polinsky MS; Baluarte HJ
    Child Nephrol Urol; 1991; 11(4):190-2. PubMed ID: 1777898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization to OKT3 monoclonal antibody in heart transplantation: correlation with early allograft loss.
    O'Connell JB; Renlund DG; Hammond EH; Wittwer CT; Yowell RL; DeWitt CW; Jones KW; Gay WA; Menlove RL; Bristow MR
    J Heart Lung Transplant; 1991; 10(2):217-21; discussion 221-2. PubMed ID: 1903303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies.
    Norman DJ; Chatenoud L; Cohen D; Goldman M; Shield CF
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):89-92. PubMed ID: 8465436
    [No Abstract]   [Full Text] [Related]  

  • 11. The incidence of antibody formation to OKT3 consequent to its use in organ transplantation.
    Carey G; Lisi PJ; Schroeder TJ
    Transplantation; 1995 Jul; 60(2):151-8. PubMed ID: 7624957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of anti-idiotypic antibodies after OKT3 treatment by flow cytometry.
    Hesse CJ; Jutte NH
    Transplantation; 1996 Jan; 61(1):169. PubMed ID: 8560562
    [No Abstract]   [Full Text] [Related]  

  • 13. Humoral immune response against OKT3.
    Chatenoud L
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):68-73. PubMed ID: 8465430
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients.
    Toyoda M; Galfayan K; Wachs K; Czer L; Jordan SC
    Clin Transplant; 1995 Dec; 9(6):472-80. PubMed ID: 8645891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spurious elevation of serum thyrotropin (TSH) after OKT3 administration.
    Goffin E; Lambert M; De Nayer P; Saint-Remy JM; Pirson Y; van Ypersele de Strihou C
    Nephrol Dial Transplant; 1994; 9(10):1500-2. PubMed ID: 7816271
    [No Abstract]   [Full Text] [Related]  

  • 16. First and second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection followed by testing for anti-OKT3 IgM and/or IgG immunization.
    Birkeland SA; Bach JF; Chatenoud L; Jørgensen KA; Strate M; Elbirk A; Rohr N; Svendsen V
    Transplant Proc; 1990 Feb; 22(1):221-2. PubMed ID: 2106740
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical role of immunologic monitoring during OKT3 treatment.
    Bhat G; Schroeder TJ
    Transplant Proc; 1997 Dec; 29(8A):21S-26S. PubMed ID: 9414670
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients.
    Niaudet P; Jean G; Broyer M; Chatenoud L
    Pediatr Nephrol; 1993 Jun; 7(3):263-7. PubMed ID: 8518095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variations in serum OKT3 concentration based upon age, sex, transplanted organ, treatment regimen, and anti-OKT3 antibody status.
    Schroeder TJ; Michael AT; First MR; Hariharan S; Bhat G; Hanto DW; Ryckman FC; Balistreri WF
    Ther Drug Monit; 1994 Aug; 16(4):361-7. PubMed ID: 7974625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
    Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.